Lactate-Driven Epigenetic Mark Accelerates Lung Aging in COPD
A histone modification triggered by lactate buildup drives lung cell senescence in COPD — and blocking it reverses damage in lab models.
Summary
Researchers at Tongji Hospital identified a specific epigenetic mark — histone H4 lysine 12 lactylation (H4K12la) — that accumulates in the lungs of COPD patients and accelerates aging of alveolar epithelial cells. Lactate, which builds up under the chronic low-oxygen conditions of COPD, chemically modifies histones, altering gene expression. H4K12la was found to upregulate CD38, an enzyme that depletes NAD+, a critical molecule for cellular energy and repair. Lower NAD+ then drives cellular senescence. Blocking this pathway — using a p300/CBP inhibitor, a CD38 inhibitor, or the NAD+ precursor NMN — reduced senescence markers and improved COPD-related pathology in both cell and animal models. These findings open new therapeutic angles targeting the lactate-epigenetics-NAD+ axis in COPD.
Detailed Summary
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide, and cellular senescence — the state where cells stop dividing and release inflammatory signals — is increasingly recognized as a core driver of lung tissue deterioration. Understanding what triggers this senescence in lung cells could unlock new treatments.
This study focused on alveolar epithelial type II cells (AEC2s), which are essential for lung repair and surfactant production. The researchers investigated whether lactate, which accumulates in the chronically hypoxic environment of COPD lungs, contributes to AEC2 senescence through epigenetic changes — specifically, a recently described modification called histone lactylation.
Using COPD cell and animal models, the team found elevated levels of histone lactylation, with site-specific analysis pinpointing H4K12la as the dominant modification. CUT&Tag sequencing revealed that H4K12la activates the CD38 gene, an enzyme that degrades NAD+. Higher CD38 activity led to reduced intracellular NAD+ levels, which in turn promoted cellular senescence — a pathway with growing relevance in aging biology.
Critically, the researchers tested three intervention strategies: inhibiting H4K12la formation with the p300/CBP inhibitor A485; blocking CD38 directly with compound 78c; and replenishing NAD+ using the precursor NMN. All three approaches reduced senescence markers and alleviated COPD-related damage in experimental models, validating the H4K12la–CD38–NAD+ axis as a druggable target.
While the findings are compelling, the study is limited to preclinical models, and translational validation in human COPD patients is needed. Nevertheless, it adds an important epigenetic dimension to NAD+ biology in lung aging and positions lactylation inhibition alongside NMN supplementation as complementary strategies worth pursuing clinically.
Key Findings
- H4K12la is the dominant histone lactylation mark elevated in COPD lung cell models.
- H4K12la upregulates CD38, depleting NAD+ and driving alveolar cell senescence.
- CUT&Tag sequencing directly linked H4K12la to CD38 gene activation.
- p300/CBP inhibitor A485 reduced H4K12la, reversed senescence, and improved COPD pathology.
- CD38 inhibitor 78c and NAD+ precursor NMN both independently reduced senescence markers.
Methodology
Study used in vitro COPD cell models and in vivo animal models to measure histone lactylation levels. CUT&Tag sequencing identified genomic targets of H4K12la. Pharmacological interventions (A485, 78c, NMN) were tested for their effects on senescence markers and lung pathology.
Study Limitations
Findings are based solely on preclinical cell and animal models; human clinical validation is absent. The specificity of H4K12la versus other lactylation sites in human COPD tissue remains to be confirmed. Long-term safety and efficacy of p300/CBP inhibition in lung tissue have not been assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: